Olin is expected to implement one of its largest cost-saving goals this year, estimated to be between $100 and $120 million. Given that we are starting to see top line recovery, mainly driven by the epoxy segment, cost savings will bring margin expansion. Momentum, growth, and profitability metrics are improving well and are superior to its peers, but the valuation remains depressed with an upside potential of 68% in case of a re-rating.
Olin remains a buy as Middle East conflict tightens global petrochemical supply, supporting US-centric producers and improving pricing power. OLN's Q1 likely marks the bottom, with Q2 expected to benefit from lower US natural gas prices and improved margins, especially in Chlor Alkali. Despite weak construction demand, supply disruptions and cost tailwinds should drive at least $150M free cash flow in 2026, with further upside possible.
CLAYTON, Mo., April 2, 2026 /PRNewswire/ -- Olin Corporation (NYSE: OLN) announced today that on Friday, May 8, 2026, at 9:00 a.m.
OLN324 demonstrated meaningfully faster and greater improvements in anatomic outcomes in DME and numerically greater vision gains sustained through 20 weeks with fewer retreatments as compared to faricimab New anatomic data demonstrates OLN324 achieves faster, greater, and more durable reductions in wAMD pigment epithelial detachment (PED) thickness versus faricimab Ollin and Innovent Biologics adva ncing OLN324 into global Phase 3 studies in DME and wAMD in 2026 SAN FRANCISCO and SUZHOU, China, March 30, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology and other major disease areas, today announced that the company's partner Ollin reported final, 20-week study completion data from its randomized, head-to-head Phase 1b JADE clinical study comparing OLN324(Innovent R&D code IBI324) , a higher-potency, smaller-format, higher-molar dose VEGF/Ang2 bispecific antibody, to faricimab (Vabysmo®), in patients with diabetic macular edema (DME) or wet (neovascular) age-related macular degeneration (wAMD). Final results released include favorable durability data for OLN324 compared to faricimab and new anatomic data showing faster, greater, and more durable control of wAMD pigment epithelial detachments (PEDs) with OLN324.
SG Americas Securities LLC raised its position in Olin Corporation (NYSE: OLN) by 142.0% in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 455,757 shares of the specialty chemicals company's stock after acquiring an additional 267,458 shares during the quarter.
/PRNewswire/ -- According to sources, the Pentagon will prohibit the use of rare earth magnet materials originating from China in U.S. military platforms
Grizzlyrock Capital sold 135,000 Olin shares in the fourth quarter; the estimated transaction value was $2.91 million (based on average Q4 2025 pricing). Meanwhile, the quarter-end position value declined by $4.07 million, reflecting both the share sale and price movements.
Choreo LLC acquired a new position in shares of Olin Corporation (NYSE: OLN) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 29,054 shares of the specialty chemicals company's stock, valued at approximately $726,000. A number of other
Shares of Olin Corporation (NYSE: OLN - Get Free Report) have been assigned a consensus rating of "Hold" from the eighteen research firms that are presently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a sell recommendation, twelve have given a hold recommendation, two have issued a buy recommendation
Amitell Capital Pte Ltd acquired a new position in Olin Corporation (NYSE: OLN) during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 154,731 shares of the specialty chemicals company's stock, valued at approximately $3,867,000. Olin comprises about 2.4% of Amitell Capital Pte Ltd's
